How Much Is Mounjaro? The Diabetes-Indicated Price, Honestly

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 10 sources cited · As of May 2026 — confirm current pricing directly with the pharmacy or manufacturer.

Key Takeaways

• Cash retail Mounjaro: approximately $1,069 per month in May 2026
• With commercial insurance and a type 2 diabetes diagnosis, copays generally land between $25 and $80; the Lilly savings card can drop eligible copays to as low as $25
• Medicare Part D covers Mounjaro for type 2 diabetes; the Part D $2,000 annual out-of-pocket cap is now in effect
• Mounjaro and Zepbound are the same molecule (tirzepatide) marketed for different indications; cash retail prices are similar
• Off-label Mounjaro use for weight loss does not qualify for savings card or insurance coverage in most plans

Direct answer

Brand Mounjaro retails at approximately $1,069 per month at U.S. cash pricing in May 2026. With commercial insurance covering it for type 2 diabetes, copays typically fall between $25 and $80. The Lilly Mounjaro Savings Card can lower eligible commercial copays to as little as $25. Medicare Part D covers Mounjaro for diabetes and benefits from the new $2,000 annual out-of-pocket cap. Confirm current pricing directly with the pharmacy or manufacturer.

Table of contents

1. What Mounjaro actually costs at retail
2. Commercial insurance and the diabetes indication
3. The Mounjaro Savings Card mechanics
4. Medicare Part D in the new cap era
5. Medicaid coverage by state
6. Pharmacy variation and discount cards
7. Mounjaro vs. Zepbound at the cash register
8. The off-label-for-weight-loss question
9. Lilly Cares patient assistance
10. What to ask your pharmacy
11. FAQ
12. Sources

What Mounjaro actually costs at retail

Mounjaro's wholesale acquisition cost sits near $1,069 monthly per Eli Lilly's published pricing. Pharmacy cash prices match WAC closely because Mounjaro is typically dispensed at or near list. Real cash quotes in May 2026 cluster between $1,000 and $1,120 across U.S. markets. Confirm current pricing directly with the pharmacy or manufacturer.

A monthly supply is four single-use autoinjector pens (one weekly dose each). Dose strengths include 2.5, 5, 7.5, 10, 12.5, and 15 mg. Cash pricing is similar across pen strengths; the 2.5 mg starter pen does not cost less than the 15 mg maintenance pen.

Commercial insurance and the diabetes indication

Mounjaro is FDA-approved for adults with type 2 diabetes as an adjunct to diet and exercise to improve glycemic control. Commercial insurance coverage for this indication is widespread; most major plans cover Mounjaro on the preferred-brand or non-preferred-brand tier.

Real copay ranges by plan tier:

Tier	Typical monthly copay
Preferred brand	$25 to $60
Non-preferred brand	$60 to $200
Specialty	20 to 40 percent coinsurance, often $200 to $400
High-deductible (pre-deductible)	Full negotiated rate, ~$700 to $900

Prior authorization is common. Plans typically require documentation of type 2 diabetes (most often A1C 6.5% or higher) and may require trial of metformin or another oral agent first. Some plans require a step through Ozempic or another GLP-1 before approving Mounjaro.

The Mounjaro Savings Card mechanics

Lilly's Mounjaro Savings Card in May 2026:

• Patients with commercial insurance covering Mounjaro for type 2 diabetes can pay as little as $25 per monthly fill
• Maximum monthly savings: up to $150 per fill
• Annual savings cap: $1,800
• Not eligible: Medicare, Medicaid, TRICARE, VA, or any federal/state-funded program
• Not eligible: uninsured patients
• Activation: through the Mounjaro.lilly.com portal or printed cards from prescribers

The card stacks on top of insurance benefits. It does not function as a coupon for cash patients to buy at a discount; the discount is computed on top of an insurance copay.

Medicare Part D in the new cap era

The Inflation Reduction Act's Medicare Part D redesign took full effect in 2025, with the annual out-of-pocket cap set at $2,000 per beneficiary in 2026. For Mounjaro patients on Medicare with type 2 diabetes:

• Initial coverage phase copays typically run $40 to $100 monthly depending on plan
• The $2,000 cap is hit fairly quickly for patients on Mounjaro (often by April or May of the calendar year)
• After the cap, the patient pays $0 for covered drugs for the rest of the year
• The MPPP (Medicare Prescription Payment Plan) lets patients spread out-of-pocket costs across the year in monthly installments

The cap fundamentally changed the Medicare math for GLP-1 patients. What was previously a $4,000 to $8,000 annual exposure is now $2,000.

Medicaid coverage by state

State Medicaid programs vary considerably in their Mounjaro coverage policies. The patterns:

• Coverage for type 2 diabetes is widespread, usually with prior authorization
• Step therapy through metformin and often another agent is common before Mounjaro is approved
• Quantity limits (typically one pen per week) are standard
• Copays are minimal where they apply, generally $0 to $4 per month

Off-label use for weight loss is not covered by any state Medicaid program as a matter of policy.

Pharmacy variation and discount cards

Pharmacy-to-pharmacy variation for Mounjaro tends to be narrower than for Ozempic. Most pharmacies price within $100 of each other. Discount card behavior:

Card	Approximate Mounjaro 1-month price, May 2026
No card, straight cash	$1,069 average
GoodRx	$990 to $1,050
SingleCare	$995 to $1,055
Costco member cash	$960 to $1,020

For diabetes patients with covered prescriptions, the savings card almost always beats discount cards. For patients whose insurance does not cover Mounjaro and who lack a path to Lilly Direct's weight-management programs (which are Zepbound, not Mounjaro), discount cards offer modest relief on cash retail.

Mounjaro vs. Zepbound at the cash register

Same drug, different label. The cash retail difference is small. The structural difference is access:

• Mounjaro: type 2 diabetes label, $1,069 retail, no manufacturer-direct vial program, standard pharmacy distribution
• Zepbound: chronic weight management and OSA labels, $1,059 retail, Lilly Direct vials at $349-$499 for cash-pay patients

Patients with diabetes typically stay on Mounjaro because insurance covers it. Patients without diabetes seeking weight loss should use Zepbound, where indication, coverage, and cash-pay programs align.

The off-label-for-weight-loss question

Mounjaro was widely prescribed off-label for weight loss in 2022-2023 before Zepbound launched. Today, with Zepbound available for the obesity indication, off-label Mounjaro for weight loss is harder to justify clinically and financially. The savings card, Lilly Cares, and most insurance plans require the prescription to match the FDA-approved indication.

Patients currently on Mounjaro for non-diabetes reasons should ask their clinician about switching to Zepbound. The molecule is identical; the relabeling opens up Lilly Direct vials (potentially $349-$499) and indication-appropriate insurance coverage.

Lilly Cares patient assistance

The Lilly Cares Foundation provides Mounjaro at no cost to qualifying uninsured low-income U.S. residents. The criteria match the Zepbound program:

• U.S. residency
• Household income at or below 400% of the federal poverty level
• Uninsured or insured without prescription coverage that includes Mounjaro
• Prescription for FDA-approved indication (type 2 diabetes)

Approval takes four to eight weeks. Most rejections are documentation issues; resubmitting with complete records often resolves them.

What to ask your pharmacy

To get accurate pricing before filling, ask these questions:

1. What is your cash price for one month of Mounjaro at this dose?
2. If I bring a GoodRx card, what would the price be?
3. If you have my insurance on file, what would my copay be?
4. Are you in network with my plan's preferred pharmacy network?
5. Is Mounjaro currently in stock or do you have to order it?

The answers vary enough that getting two or three quotes can change the monthly bill by $50 to $100.

FAQ

How much is Mounjaro in 2026? About $1,069 per month at U.S. cash retail as of May 2026.

Does insurance cover Mounjaro? Yes, most commercial and Medicare Part D plans cover Mounjaro for type 2 diabetes. Copays typically $25 to $80 with the savings card layered on.

What is the Mounjaro savings card? A commercial-insurance copay card that lowers eligible patients' costs to as little as $25 per fill, subject to caps. Not available to Medicare/Medicaid patients.

Is Mounjaro the same as Zepbound? Same active ingredient (tirzepatide), different FDA-approved indications. Mounjaro for diabetes, Zepbound for obesity and OSA.

Can I use a Mounjaro coupon if I don't have diabetes? No. The savings card requires a diabetes indication. Off-label prescriptions do not qualify.

How much is Mounjaro at Costco? Generally $960 to $1,020 with Costco membership. Pricing varies by location.

Does Medicare cover Mounjaro? Yes, for type 2 diabetes. The new Part D $2,000 annual out-of-pocket cap caps total exposure.

Will Mounjaro get cheaper soon? Generic tirzepatide is years away. Medicare negotiation under the IRA could lower Part D pricing in future cycles.

What if my insurance denies Mounjaro coverage? Appeal with documentation of medical necessity. Plans can be persuaded by A1C trajectories, comorbidity profiles, and prior trial of metformin.

Are there compounded tirzepatide alternatives for diabetes patients? Compounded tirzepatide is generally prescribed for weight loss, not diabetes. For diabetes patients, brand Mounjaro with insurance is almost always the better path.

Can I switch from Mounjaro to Zepbound for a lower price? Possibly, if you meet Zepbound's indications. The molecule is identical. Talk to your prescriber.

Sources

1. Eli Lilly and Company. Mounjaro Wholesale Acquisition Cost and Savings Card documentation. Mounjaro.lilly.com. 2026.
2. U.S. Food and Drug Administration. Mounjaro (tirzepatide) prescribing information. 2024.
3. Centers for Medicare and Medicaid Services. Medicare Part D 2026 redesign and out-of-pocket cap. CMS.gov. 2026.
4. American Diabetes Association. Standards of Medical Care in Diabetes. 2026.
5. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
6. Kaiser Family Foundation. Prescription Drug Coverage in Commercial and Medicare Plans, 2025-2026.
7. Lilly Cares Foundation. Patient assistance program documentation. 2026.
8. State Medicaid agencies. Preferred drug list documentation for tirzepatide. Multiple states, 2025-2026.
9. Inflation Reduction Act of 2022. Medicare Drug Price Negotiation Provisions.
10. GoodRx Research. Drug Price Trends Report. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends connects patients with independent licensed providers and partnered pharmacies. We do not directly prescribe, manufacture, or dispense medication. Clinical decisions are made by the treating provider following individual evaluation.

Compounded Medication Notice. Where this article references compounded tirzepatide, it describes products prepared by 503A state-licensed pharmacies in response to specific prescriptions. Compounded products are not FDA-approved and not interchangeable with brand Mounjaro or brand Zepbound.

Results Disclaimer. Pricing data reflects May 2026 information from manufacturer, retail, and program sources. Manufacturer programs, formulary placement, and pharmacy retail change frequently. Verify current pricing with the pharmacy or manufacturer before relying on these numbers.

Trademark Notice. Mounjaro, Zepbound, Lilly Direct, and Lilly Cares are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and NovoCare are registered trademarks of Novo Nordisk A/S. Costco, GoodRx, and SingleCare are property of their respective owners. FormBlends is not affiliated with any manufacturer or retailer named.